primaquine and Recrudescence
primaquine has been researched along with Recrudescence in 172 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor." | 9.30 | Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019) |
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 9.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
" Artesunate cleared parasitemia significantly faster than chloroquine." | 9.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 9.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
"Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-bone Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack." | 9.04 | Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. ( Clyde, DF; McCarthy, VC, 1977) |
"Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')." | 8.98 | Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018) |
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 7.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
"After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria." | 7.78 | Reinventing primaquine for endemic malaria. ( Baird, JK, 2012) |
" Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses." | 6.94 | Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020) |
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P." | 6.73 | High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008) |
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 6.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0." | 6.61 | Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019) |
"vivax relapse is a major global public health concern." | 6.53 | Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016) |
"Tafenoquine is a new alternative with a longer half-life." | 6.52 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015) |
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia." | 6.52 | Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015) |
"Plasmodium vivax malaria is considered a major threat to malaria eradication." | 5.91 | Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023) |
"Malaria is a major cause of death in low-income countries." | 5.72 | Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022) |
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes." | 5.72 | Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
"Primaquine was effective in preventing P." | 5.72 | Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022) |
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020." | 5.72 | Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022) |
"vivax malaria was higher in children 1 to <5 years of age (49." | 5.46 | Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017) |
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine." | 5.40 | Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014) |
"Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P." | 5.33 | Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. ( Baird, JK; Hill, DR; Lewis, LS; Magill, AJ; Parise, ME; Ryan, ET, 2006) |
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 5.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor." | 5.30 | Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019) |
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine." | 5.30 | [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997) |
"Radical cure of Plasmodium vivax malaria requires treatment with a blood schizonticide and a hypnozoitocide (primaquine) to eradicate the dormant liver stages." | 5.27 | A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. ( Bava, A; Bhat, K; Brahmarouphu, G; Channabasavaiah, JP; Guddattu, V; Kulavalli, S; Saadi, AV; Saravu, K; Satyamoorthy, K; Srinivas, NK; Tellapragada, C; Umakanth, S; Xavier, W, 2018) |
" Artesunate cleared parasitemia significantly faster than chloroquine." | 5.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
"Chloroquine has been the standard treatment for Plasmodium vivax malaria for more than 40 years in most regions of the world." | 5.09 | Chloroquine sensitivity of Plasmodium vivax in Thailand. ( Bussaratid, V; Chalermrut, K; Chokjindachai, W; Krudsood, S; Looareesuwan, S; Singhasivanon, P; Treeprasertsuk, S; Viriyavejakul, P; Walsh D, S; White, J; Wilairatana, P, 1999) |
"In an investigation of relapse patterns, 5541 cases of Plasmodium vivax malaria, from four major industrial complexes, each received at least one, 5-day course of primaquine (at 15 mg/day)." | 5.09 | Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. ( Dua, VK; Sharma, VP, 2001) |
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 5.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
"Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-bone Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack." | 5.04 | Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. ( Clyde, DF; McCarthy, VC, 1977) |
"Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure." | 4.98 | The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Erhart, A; Gomes, MSM; Gonzalez-Ceron, L; Grigg, MJ; Guerin, PJ; Heidari, A; Humphreys, GS; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Sutanto, I; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Tran, HT; Valecha, N; Vieira, JLF; Wangchuk, S; White, NJ; William, T; Woodrow, CJ; Zuluaga-Idarraga, L, 2018) |
"Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')." | 4.98 | Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018) |
" Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria." | 4.93 | Management of relapsing Plasmodium vivax malaria. ( Chu, CS; White, NJ, 2016) |
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 3.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
"Control of vivax malaria is challenging due to persistence of hypnozoites causing relapses and safety concerns with primaquine in G6PD deficient individuals." | 3.81 | The footprints of relapsing malaria in southwest Delhi, India. ( Anvikar, AR; Nagpal, BN; Savargaonkar, D; Srivastava, B; Valecha, N, 2015) |
"Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal therapy against relapse requires primaquine, which causes a mild to severe acute hemolytic anemia in G6PD deficient patients." | 3.81 | G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria. ( Baird, JK; Baramuli, V; Coutrier, FN; Elvira, R; Elyazar, I; Harahap, AR; Noviyanti, R; Ridenour, C; Sadhewa, A; Satyagraha, AW, 2015) |
"Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure." | 3.80 | Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014) |
"Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium vivax malaria." | 3.80 | The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. ( Baird, JK; Crenna-Darusallam, C; Ingram, RJ; Noviyanti, R; Soebianto, S, 2014) |
"Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections." | 3.79 | Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. ( Alenazi, T; Bright, AT; Houston, S; Paganotti, GM; Shokoples, S; Tarning, J; White, NJ; Winzeler, EA; Yanow, SK, 2013) |
"After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria." | 3.78 | Reinventing primaquine for endemic malaria. ( Baird, JK, 2012) |
"9 per cent relapse rate after administration of radical treatment of primaquine / 15 mg daily for 5 days as followed under the National Malaria Eradication Programme." | 3.67 | Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.). ( Dua, VK; Sharma, VP; Sinha, S, 1989) |
"vivax recurrence between days 7 and 90 was investigated by Cox regression analysis." | 3.01 | Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Awab, GR; Baird, JK; Brasil, LW; Chu, CS; Commons, RJ; Cui, L; Daher, A; Dini, S; do Socorro M Gomes, M; Gonzalez-Ceron, L; Guerin, PJ; Hwang, J; Karunajeewa, H; Lacerda, MVG; Ladeia-Andrade, S; Leslie, T; Ley, B; Lidia, K; Llanos-Cuentas, A; Longley, RJ; Mehdipour, P; Monteiro, WM; Pereira, DB; Price, RN; Rajasekhar, M; Rijal, KR; Saravu, K; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, PV; Thriemer, K; Vieira, JLF; White, NJ; Zaloumis, S; Zuluaga-Idarraga, LM, 2023) |
" Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses." | 2.94 | Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020) |
"The median time to recurrence of P." | 2.94 | The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. ( Adhikari, B; Cobelens, F; Day, NPJ; Dhorda, M; Dondorp, AM; Henriques, G; Imwong, M; Mayxay, M; Mukaka, M; Newton, PN; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Sirithiranont, P; van Leth, F; von Seidlein, L; White, NJ, 2020) |
"We show that individual vivax malaria recurrences can be characterised probabilistically by combined modelling of time-to-event and genetic data within a framework incorporating identity-by-descent." | 2.90 | Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. ( Buckee, CO; Chu, CS; Day, NPJ; Duanguppama, J; Imwong, M; Neafsey, DE; Nosten, F; Puaprasert, K; Taylor, AR; Watson, JA; White, NJ, 2019) |
"vivax malaria were treated with AS/SP." | 2.87 | Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018) |
"Some parasite recurrences were detected by PCR and/or serological testing." | 2.80 | Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. ( Betanzos, AF; Galindo-Virgen, S; Gonzalez-Ceron, L; Palomeque, OL; Rodriguez, MH; Rosales, AF; Sandoval, MA; Santillan, F, 2015) |
" We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy." | 2.80 | Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. ( Baird, JK; Basri, H; Chand, K; Djoko, D; Duparc, S; Ekasari, T; Ekawati, LL; Elyazar, I; Nelwan, EJ; Noviyanti, R; Setiabudy, R; Subekti, D; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2015) |
"Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P." | 2.77 | Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. ( Alonso, PL; Bassat, Q; Betuela, I; de Lazzari, E; Del Portillo, HA; Kiniboro, B; Mueller, I; Rosanas-Urgell, A; Samol, L; Siba, P; Stanisic, DI, 2012) |
"This suggested that 32 of the 47 recurrences were probable relapses of which 22 (69%) were genetically homologous." | 2.77 | Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. ( Addy, M; Day, NP; Dondorp, AM; Imwong, M; Kim, JR; Maji, AK; Nandy, A; Pukrittayakamee, S; White, NJ, 2012) |
"A practical radical treatment for vivax malaria is essential for control and elimination of the disease." | 2.73 | A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. ( Erasmus, P; Kolaczinski, J; Leslie, T; Mayan, I; Mohammed, N; Rowland, M; Whitty, CJ, 2008) |
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P." | 2.73 | High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008) |
"FDA for the treatment of P." | 2.72 | Tafenoquine for ( Gautam, CS; Sharma, J; Singh, H; Singh, J, 2021) |
"Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia." | 2.70 | Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. ( Ayomi, E; Baird, JK; Basri, H; Fryauff, DJ; Hoffman, SL; Sutanihardja, A; Wiady, I, 2002) |
"Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0." | 2.68 | Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997) |
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 2.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
" We do not know whether there is a difference in adverse events resulting in discontinuation of treatment with the high-standard dosage (RR 4." | 2.66 | Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. ( Bergman, H; Daher, A; Graves, PM; Milligan, R; Villanueva, G, 2020) |
"vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan." | 2.61 | The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019) |
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0." | 2.61 | Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019) |
"Malaria recurrences after an initially successful therapy and malarial fever occurring a long time after infection are well-known problems in malariology." | 2.53 | Clinical implications of a gradual dormancy concept in malaria. ( Franken, G; Holtfreter, MC; Labisch, A; Mehlhorn, H; Richter, J; Walter, S, 2016) |
"vivax relapse is a major global public health concern." | 2.53 | Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016) |
"Tafenoquine is a new alternative with a longer half-life." | 2.52 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015) |
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia." | 2.52 | Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015) |
" For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents." | 2.41 | [Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000) |
"Plasmodium vivax malaria is considered a major threat to malaria eradication." | 1.91 | Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023) |
"Malaria recurrence was defined as more than one episode of vivax malaria in the same or consecutive years." | 1.72 | Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. ( Baek, JH; Cho, SH; Choi, H; Choi, S; Kim, M; Kim, MJ; Kim, YC; Kwak, YG; Kwon, JR; Lee, SE; Oh, HS; Park, S; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
"Primaquine was effective in preventing P." | 1.72 | Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022) |
"Malaria is a major cause of death in low-income countries." | 1.72 | Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022) |
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes." | 1.72 | Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020." | 1.72 | Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022) |
"Relapses in vivax malaria have posed great challenges for malaria control, and they also account for a great proportion of reported cases." | 1.62 | Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. ( Brito-Sousa, JD; Dinelly, KMO; Lacerda, MVG; Melo, GC; Monteiro, WM; Omena, AG; Peterka, C; Rodovalho, S; Sampaio, VS; Silva, MGO; Siqueira, AM; Vitor-Silva, S, 2021) |
"We compare recurrence rates observed after primary P." | 1.56 | Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020) |
" vivax relapses after a correct treatment and, especially, it should be considered in any study of dosage and duration of primaquine treatment." | 1.56 | Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. ( Bernal Fernández, MJ; Domingo García, D; Gutierrez Liarte, Á; Lanza Suárez, M; Lombardia González, C; Martin Ramírez, A; Rubio, JM; Soler Maniega, T, 2020) |
"There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1." | 1.51 | Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019) |
"Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models." | 1.51 | Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. ( A Cleves, M; Aguirre, AR; D'Alessandro, U; Erhart, A; Hens, N; Le, HX; Nguyen, HV; Nguyen, TT; Nguyen, VV; Nguyen, XX; Pham, TV; Rosanas-Urgell, A; Speybroeck, N; Tran, DT, 2019) |
"vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0." | 1.51 | Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. ( Adhikari, B; Banjara, MR; Chotivanich, K; Das Thakur, G; Day, NPJ; Ghimire, P; Hanboonkunupakarn, B; Imwong, M; Pukrittayakamee, S; Rijal, KR; White, NJ, 2019) |
"Ovale malaria is considered to feature relapses by liver hypnozoites although scientific evidence for this paradigm is scarce." | 1.48 | Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection. ( Auer, H; Fuehrer, HP; Groger, M; Lagler, H; Ramharter, M; Veletzky, L; Walochnik, J, 2018) |
"vivax malaria episode until the recurrence did not differ between patients with AS of ≤ 1 versus ≥ 1." | 1.48 | CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( Almeida, ACG; Brasil, LW; Kühn, A; Lacerda, MVG; Monteiro, WM; Ramasawmy, R; Rodrigues-Soares, F; Santoro, AB; Suarez-Kurtz, G, 2018) |
"The developed model to predict recurrence was found to be of good accuracy and could be a useful tool in targeting patients at a higher risk for recurrence for closer monitoring during follow-up, after treatment with primaquine." | 1.46 | A clinical tool to predict Plasmodium vivax recurrence in Malaysia. ( Islahudin, F; Kumolosasi, E; Makmor-Bakry, M; Mat Ariffin, N, 2017) |
"vivax malaria was higher in children 1 to <5 years of age (49." | 1.46 | Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017) |
"Plasmodium malariae is the only human malaria parasite species with a 72-hour intraerythrocytic cycle and the ability to persist in the host for life." | 1.46 | Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. ( Anstey, NM; Auburn, S; Berriman, M; Huang, GKL; Marfurt, J; Marr, I; Newbold, CI; Otto, TD; Price, RN; Rutledge, GG; Sanders, M; White, NJ, 2017) |
"Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military." | 1.42 | Repeated Plasmodium vivax malaria relapses in a Peruvian sailor. ( Cavalcanti, S; Gonzalez, S; Lescano, AG; McFarland, AP; Mercado, A; Sanchez, JF; Ventocilla, JA, 2015) |
"Malaria is considered as one of the most threatening diseases affecting peacekeeping forces serving in malaria endemic countries." | 1.40 | A retrospective study on imported malaria in Jordan. 1. Malaria among Jordanian UN peacekeeping forces. ( Al-Rashadan, M; Amr, ZS; Bani Hani, R; Kanani, K; Shadfan, B, 2014) |
"vivax malaria is a substantial risk." | 1.40 | Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014) |
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine." | 1.40 | Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014) |
" The overall median time to relapse, obtained by the Kaplan-Meier method, was 108 days, and the survival analysis demonstrated an association between non-weight-adjusted primaquine dosing and the occurrence of relapse (p < 0." | 1.38 | Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. ( Brasil, P; Campos, DP; Costa, AP; Daniel-Ribeiro, CT; Guaraldo, L; Pedro, RS, 2012) |
"Here we describe high rates of P." | 1.35 | Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009) |
"Relapses were diagnosed in 18% of all malaria episodes." | 1.33 | Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. ( Bottieau, E; Clerinx, J; Colebunders, R; Van Den Ende, J; Van Den Enden, E; Van Esbroeck, M; Van Gompel, A, 2006) |
"Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P." | 1.33 | Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. ( Baird, JK; Hill, DR; Lewis, LS; Magill, AJ; Parise, ME; Ryan, ET, 2006) |
" Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack." | 1.30 | Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. ( DeFraites, RF; Kain, KC; Magill, AJ; Smoak, BL; Wellde, BT, 1997) |
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine." | 1.30 | [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997) |
"Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency." | 1.29 | [Recurrence problems with preventive primaquine treatment in patients with malaria]. ( Bygbjerg, IC; Rønn, AM, 1993) |
"Vivax malaria is the most frequent among imported malaria in Japan, comprising about 60% of the total cases." | 1.29 | [A study of relapsed cases of vivax malaria after the standard primaquine therapy]. ( Kimura, M; Ohtomo, H; Takizawa, Y; Tomizawa, I, 1996) |
"Primaquine has been found adequate to prevent relapse in more than 90% vivax cases, while efficacy of chloroquine-pyrimethamine and chloroquine alone was almost comparable." | 1.29 | Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. ( Bhatt, RM; Sharma, SK; Sharma, VP; Srivastava, HC, 1996) |
"Primaquine (30 mg) was given orally to all patients except three; two of these patients received 15 mg of the drug daily and another 30 mg of drug on alternate days." | 1.28 | Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. ( Black, JR; Murphy, RL; Noskin, GA; Phair, JP, 1992) |
"Chloroquine was most frequently used among antimalarial agents (in 123 cases, 65% of the total) for suppressing acute attacks." | 1.28 | [Clinical evaluation of antimalarial drugs]. ( Shimada, K; Tanabe, K, 1990) |
"The actual situation of the treatment of malaria for the past 10 years in Japan was investigated and analyzed." | 1.27 | Clinical evaluation of antimalarial regimens in Japan. ( Hioki, A; Ishizaki, T; Nakabayashi, T; Ohtomo, H; Tanabe, K, 1987) |
Research
Studies (172)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 24 (13.95) | 18.7374 |
1990's | 28 (16.28) | 18.2507 |
2000's | 20 (11.63) | 29.6817 |
2010's | 69 (40.12) | 24.3611 |
2020's | 31 (18.02) | 2.80 |
Authors
Authors | Studies |
---|---|
Zhang, L | 1 |
Sathunuru, R | 1 |
Caridha, D | 1 |
Pybus, B | 1 |
O'Neil, MT | 1 |
Kozar, MP | 1 |
Lin, AJ | 1 |
Aung, PL | 2 |
Soe, MT | 1 |
Soe, TN | 1 |
Oo, TL | 1 |
Aung, PP | 1 |
Khin, A | 1 |
Thi, A | 1 |
Phuanukoonnon, S | 1 |
Okanurak, K | 1 |
Cui, L | 4 |
Kyaw, MP | 2 |
Parker, DM | 2 |
Nain, M | 1 |
Mohan, M | 1 |
Sharma, A | 1 |
Choi, S | 2 |
Choi, H | 2 |
Park, SY | 2 |
Kwak, YG | 2 |
Song, JE | 2 |
Shin, SY | 2 |
Baek, JH | 2 |
Shin, HI | 2 |
Oh, HS | 2 |
Kim, YC | 2 |
Yeom, JS | 3 |
Han, JH | 1 |
Kim, MJ | 2 |
Chamma-Siqueira, NN | 2 |
Negreiros, SC | 1 |
Ballard, SB | 1 |
Farias, S | 2 |
Silva, SP | 1 |
Chenet, SM | 2 |
Santos, EJM | 1 |
Pereira de Sena, LW | 1 |
Póvoa da Costa, F | 1 |
Cardoso-Mello, AGN | 1 |
Marchesini, PB | 1 |
Peterka, CRL | 1 |
Viana, GMR | 2 |
Macedo de Oliveira, A | 2 |
Llanos-Cuentas, A | 2 |
Manrrique, P | 1 |
Rosas-Aguirre, A | 1 |
Herrera, S | 1 |
Hsiang, MS | 1 |
Gandrala, D | 2 |
Gupta, N | 2 |
Lavu, A | 2 |
Nallapati, VT | 2 |
Guddattu, V | 3 |
Saravu, K | 6 |
Brito-Sousa, JD | 2 |
Phanor, J | 1 |
Balieiro, PCDS | 1 |
Silva-Neto, AV | 1 |
Cordeiro, JSM | 1 |
Vitor-Silva, S | 2 |
Mendes, M | 1 |
Sampaio, VS | 2 |
Melo, GC | 2 |
Lacerda, M | 1 |
Monteiro, W | 1 |
Watson, JA | 4 |
Nekkab, N | 1 |
White, M | 1 |
Sharma, J | 1 |
Gautam, CS | 1 |
Singh, H | 1 |
Singh, J | 1 |
Suh, J | 1 |
Kim, JH | 1 |
Kim, JD | 1 |
Kim, C | 1 |
Choi, JY | 1 |
Lee, J | 1 |
Taylor, WRJ | 4 |
Nguyen Pouplin, J | 1 |
Daher, A | 7 |
White, NJ | 20 |
Markus, MB | 2 |
Cho, SH | 1 |
Lee, SE | 1 |
Kwon, JR | 1 |
Park, S | 1 |
Kim, M | 1 |
Win, KM | 1 |
Ring, Z | 1 |
Linn, NYY | 1 |
Nguitragool, W | 1 |
Sattabongkot, J | 1 |
Lawpoolsri, S | 1 |
Mehdipour, P | 1 |
Rajasekhar, M | 1 |
Dini, S | 1 |
Zaloumis, S | 1 |
Abreha, T | 3 |
Adam, I | 2 |
Awab, GR | 3 |
Baird, JK | 14 |
Brasil, LW | 2 |
Chu, CS | 7 |
do Socorro M Gomes, M | 1 |
Gonzalez-Ceron, L | 4 |
Hwang, J | 3 |
Karunajeewa, H | 2 |
Lacerda, MVG | 4 |
Ladeia-Andrade, S | 1 |
Leslie, T | 3 |
Ley, B | 5 |
Lidia, K | 3 |
Longley, RJ | 1 |
Monteiro, WM | 4 |
Pereira, DB | 3 |
Rijal, KR | 2 |
Sutanto, I | 5 |
Thanh, PV | 1 |
Thriemer, K | 5 |
Vieira, JLF | 2 |
Zuluaga-Idarraga, LM | 2 |
Guerin, PJ | 3 |
Price, RN | 9 |
Simpson, JA | 6 |
Commons, RJ | 3 |
He, X | 1 |
Pan, M | 1 |
Zeng, W | 1 |
Zou, C | 1 |
Pi, L | 1 |
Qin, Y | 1 |
Zhao, L | 1 |
Qin, P | 1 |
Lu, Y | 1 |
Huang, Y | 1 |
Yang, Z | 1 |
Kostić, M | 1 |
Milosavljević, MN | 1 |
Stefanović, S | 1 |
Ranković, G | 1 |
Janković, SM | 1 |
Anstey, NM | 4 |
Assefa, A | 2 |
Barber, BE | 2 |
Dahal, P | 2 |
Davis, TME | 1 |
Dondorp, AM | 4 |
Grigg, MJ | 2 |
Humphreys, GS | 2 |
Laman, M | 1 |
Moore, BR | 1 |
Mueller, I | 3 |
Nosten, F | 6 |
Pasaribu, AP | 2 |
Phyo, AP | 4 |
Poespoprodjo, JR | 2 |
Sibley, CH | 2 |
Stepniewska, K | 2 |
Thwaites, G | 2 |
Hien, TT | 3 |
William, T | 2 |
Woodrow, CJ | 2 |
Taylor, AR | 2 |
Puaprasert, K | 1 |
Duanguppama, J | 1 |
Day, NPJ | 4 |
Neafsey, DE | 1 |
Buckee, CO | 1 |
Imwong, M | 9 |
Kagaya, W | 1 |
Gitaka, J | 1 |
Chan, CW | 1 |
Kongere, J | 1 |
Md Idris, Z | 1 |
Deng, C | 1 |
Kaneko, A | 1 |
Phommasone, K | 2 |
van Leth, F | 2 |
Henriques, G | 1 |
Pongvongsa, T | 2 |
Adhikari, B | 3 |
Peto, TJ | 2 |
Promnarate, C | 3 |
Dhorda, M | 3 |
Sirithiranont, P | 2 |
Mukaka, M | 2 |
Peerawaranun, P | 2 |
Cobelens, F | 2 |
Newton, PN | 2 |
von Seidlein, L | 4 |
Mayxay, M | 2 |
Landier, J | 1 |
Nguyen, TN | 1 |
Tripura, R | 1 |
Lwin, KM | 2 |
Kajeechiwa, L | 1 |
Thwin, MM | 1 |
Wiladphaingern, J | 3 |
Nosten, S | 1 |
Proux, S | 3 |
Nguon, C | 1 |
Davoeung, C | 1 |
Rekol, H | 1 |
Chotivanich, K | 2 |
Hanboonkunupakarn, B | 2 |
Jittmala, P | 1 |
Cheah, PY | 4 |
Pukrittayakamee, S | 5 |
Thwaites, GE | 1 |
Nosten, FH | 1 |
Silvino, ACR | 1 |
Kano, FS | 1 |
Costa, MA | 1 |
Fontes, CJF | 1 |
Soares, IS | 2 |
de Brito, CFA | 1 |
Carvalho, LH | 2 |
Sousa, TN | 2 |
Devine, A | 2 |
Howes, RE | 2 |
Price, DJ | 1 |
Moore, KA | 3 |
Dittrich, S | 1 |
Spring, MD | 1 |
Lon, C | 1 |
Sok, S | 1 |
Sea, D | 1 |
Wojnarski, M | 1 |
Chann, S | 1 |
Kuntawunginn, W | 1 |
Kheang Heng, T | 1 |
Nou, S | 1 |
Arsanok, M | 1 |
Sriwichai, S | 1 |
Vanachayangkul, P | 2 |
Lin, JT | 1 |
Manning, JE | 1 |
Jongsakul, K | 2 |
Pichyangkul, S | 1 |
Satharath, P | 1 |
Smith, PL | 1 |
Dysoley, L | 1 |
Saunders, DL | 1 |
Waters, NC | 1 |
Mat Salleh, NH | 1 |
Rahman, MFA | 1 |
Samsusah, S | 1 |
De Silva, JR | 1 |
Ng, DC | 1 |
Ghozali, AH | 1 |
Tan, JH | 1 |
Lai, MY | 1 |
Amir, A | 1 |
Liew, JWK | 1 |
Lau, YL | 1 |
Mhamilawa, LE | 1 |
Ngasala, B | 1 |
Morris, U | 1 |
Kitabi, EN | 1 |
Barnes, R | 1 |
Soe, AP | 1 |
Mmbando, BP | 1 |
Björkman, A | 2 |
Mårtensson, A | 1 |
Martin Ramírez, A | 1 |
Lombardia González, C | 1 |
Soler Maniega, T | 1 |
Gutierrez Liarte, Á | 1 |
Domingo García, D | 1 |
Lanza Suárez, M | 1 |
Bernal Fernández, MJ | 1 |
Rubio, JM | 1 |
Corder, RM | 1 |
de Lima, ACP | 1 |
Khoury, DS | 1 |
Docken, SS | 1 |
Davenport, MP | 1 |
Ferreira, MU | 2 |
Milligan, R | 2 |
Villanueva, G | 1 |
Bergman, H | 1 |
Graves, PM | 2 |
Rodrigo, C | 2 |
Rajapakse, S | 2 |
Fernando, D | 1 |
Dinelly, KMO | 1 |
Silva, MGO | 1 |
Siqueira, AM | 2 |
Peterka, C | 1 |
Rodovalho, S | 1 |
Omena, AG | 1 |
Wångdahl, A | 1 |
Sondén, K | 1 |
Wyss, K | 1 |
Stenström, C | 1 |
Björklund, D | 1 |
Zhang, J | 1 |
Hervius Askling, H | 1 |
Carlander, C | 1 |
Hellgren, U | 1 |
Färnert, A | 1 |
Rutledge, GG | 1 |
Marr, I | 1 |
Huang, GKL | 1 |
Auburn, S | 2 |
Marfurt, J | 3 |
Sanders, M | 1 |
Berriman, M | 1 |
Newbold, CI | 1 |
Otto, TD | 1 |
Maneerattanasak, S | 1 |
Gosi, P | 1 |
Krudsood, S | 3 |
Chimma, P | 1 |
Tongshoob, J | 1 |
Mahakunkijcharoen, Y | 1 |
Sukasem, C | 1 |
Snounou, G | 2 |
Khusmith, S | 1 |
Wampfler, R | 1 |
Hofmann, NE | 1 |
Karl, S | 1 |
Betuela, I | 2 |
Kinboro, B | 1 |
Lorry, L | 1 |
Silkey, M | 1 |
Robinson, LJ | 1 |
Felger, I | 1 |
Douglas, NM | 1 |
Patriani, D | 1 |
Malloy, MJ | 1 |
Kenangalem, E | 1 |
Sugiarto, P | 1 |
Soenarto, Y | 1 |
Mat Ariffin, N | 1 |
Islahudin, F | 1 |
Kumolosasi, E | 1 |
Makmor-Bakry, M | 1 |
Battle, KE | 1 |
Rodrigues-Soares, F | 1 |
Santoro, AB | 1 |
Almeida, ACG | 1 |
Kühn, A | 1 |
Ramasawmy, R | 1 |
Suarez-Kurtz, G | 1 |
Veletzky, L | 1 |
Groger, M | 1 |
Lagler, H | 1 |
Walochnik, J | 1 |
Auer, H | 1 |
Fuehrer, HP | 1 |
Ramharter, M | 1 |
Steinkamp, N | 1 |
Hamid, MMA | 1 |
Elobied, ME | 1 |
Mahgoub, NS | 1 |
Boshara, SA | 1 |
Elsafi, HMH | 1 |
Gumaa, SA | 1 |
Hamid, T | 1 |
Abdelbagi, H | 1 |
Basheir, HM | 1 |
Chen, I | 1 |
Gosling, R | 1 |
Recht, J | 1 |
Ashley, EA | 1 |
Sümer, Ş | 1 |
Aktuğ Demir, N | 1 |
Ural, O | 1 |
Çimen, G | 1 |
Yalçınkaya, E | 1 |
Win, HH | 2 |
San, T | 1 |
Aung, AA | 1 |
Raksapraidee, R | 2 |
Carrara, VI | 2 |
Bancone, G | 2 |
Watson, J | 3 |
Sriprawat, K | 2 |
Winterberg, M | 1 |
Chue, AL | 1 |
Tarning, J | 3 |
Alemu, SG | 1 |
Añez, A | 1 |
Borghini-Fuhrer, I | 1 |
D'Alessandro, U | 2 |
de Vries, PJ | 1 |
Erhart, A | 2 |
Gomes, MSM | 1 |
Heidari, A | 1 |
Kager, PA | 1 |
Ketema, T | 1 |
Khan, WA | 1 |
Phan, GT | 1 |
Rowland, M | 2 |
Tran, BQ | 1 |
Tran, HT | 1 |
Valecha, N | 2 |
Wangchuk, S | 1 |
Zuluaga-Idarraga, L | 1 |
Tellapragada, C | 1 |
Kulavalli, S | 1 |
Xavier, W | 1 |
Umakanth, S | 1 |
Brahmarouphu, G | 1 |
Srinivas, NK | 1 |
Channabasavaiah, JP | 1 |
Bava, A | 1 |
Saadi, AV | 1 |
Satyamoorthy, K | 1 |
Bhat, K | 1 |
Redditt, V | 1 |
Bogoch, I | 1 |
Rashid, M | 1 |
Silva, JCAL | 1 |
Stevens, A | 1 |
Marchesini, P | 2 |
Fontes, CJ | 3 |
Ter Kuile, FO | 1 |
Lalloo, DG | 1 |
Ghimire, P | 1 |
Banjara, MR | 1 |
Das Thakur, G | 1 |
Turner, C | 1 |
Poe, NP | 1 |
Yotyingaphiram, W | 1 |
Thinraow, S | 1 |
Wilairisak, P | 1 |
Paw, MK | 1 |
Lee, SJ | 1 |
Jeeyapant, A | 1 |
Chen, N | 1 |
Dowd, S | 1 |
Gatton, ML | 1 |
Auliff, A | 1 |
Edstein, MD | 1 |
Cheng, Q | 1 |
Quinn, JC | 1 |
McCarthy, S | 1 |
Green, JA | 1 |
Koh, GCKW | 1 |
Duparc, S | 2 |
Pham, TV | 1 |
Nguyen, HV | 1 |
Aguirre, AR | 1 |
Nguyen, VV | 1 |
A Cleves, M | 1 |
Nguyen, XX | 1 |
Nguyen, TT | 1 |
Tran, DT | 1 |
Le, HX | 1 |
Hens, N | 1 |
Rosanas-Urgell, A | 2 |
Speybroeck, N | 1 |
Rosenthal, PJ | 1 |
Yuentrakul, P | 1 |
Assawariyathipat, T | 1 |
Chand, K | 2 |
Chau, NH | 1 |
Dong, LT | 1 |
Degaga, TS | 1 |
Ekawati, LL | 2 |
Fahmi, F | 1 |
Hailu, A | 1 |
Hasanzai, MA | 1 |
Khu, H | 1 |
Lubell, Y | 1 |
Mohammad, H | 1 |
Naddim, MN | 1 |
Pasaribu, S | 1 |
Rahim, AG | 1 |
Solomon, H | 1 |
Sudoyo, H | 2 |
Thanh, NV | 1 |
Tuyet-Trinh, NT | 1 |
Waithira, N | 1 |
Woyessa, A | 1 |
Yamin, FY | 1 |
Dondorp, A | 1 |
Day, NP | 3 |
Bright, AT | 1 |
Alenazi, T | 1 |
Shokoples, S | 1 |
Paganotti, GM | 1 |
Houston, S | 1 |
Winzeler, EA | 1 |
Yanow, SK | 1 |
Kristensen, KL | 1 |
Dragsted, UB | 1 |
Bennett, JW | 1 |
Pybus, BS | 1 |
Yadava, A | 1 |
Tosh, D | 1 |
Sousa, JC | 1 |
McCarthy, WF | 1 |
Deye, G | 1 |
Melendez, V | 1 |
Ockenhouse, CF | 1 |
Nacher, M | 2 |
Stefani, A | 1 |
Basurko, C | 2 |
Lemonnier, D | 1 |
Djossou, F | 1 |
Demar, M | 1 |
Elenga, N | 1 |
Brousse, P | 1 |
Ville, M | 1 |
Carme, B | 2 |
Biamonte, MA | 1 |
Kanani, K | 1 |
Amr, ZS | 1 |
Shadfan, B | 1 |
Al-Rashadan, M | 1 |
Bani Hani, R | 1 |
Durand, S | 1 |
Cabezas, C | 1 |
Lescano, AG | 2 |
Galvez, M | 1 |
Gutierrez, S | 1 |
Arrospide, N | 1 |
Alvarez, C | 1 |
Santolalla, ML | 1 |
Bacon, DJ | 1 |
Graf, PC | 1 |
Møller, CH | 1 |
David, K | 1 |
Dos-Santos, JC | 1 |
Angerami, RN | 1 |
Castiñeiras, CM | 1 |
Lopes, SC | 1 |
Albrecht, L | 1 |
Garcia, MT | 1 |
Levy, CE | 1 |
Moretti, ML | 1 |
Lacerda, MV | 1 |
Costa, FT | 1 |
Saunders, D | 1 |
Imerbsin, R | 1 |
Khemawoot, P | 1 |
Siripokasupkul, R | 1 |
Tekwani, BL | 1 |
Sampath, A | 1 |
Nanayakkara, NP | 1 |
Ohrt, C | 1 |
Lanteri, C | 1 |
Gettyacamin, M | 1 |
Teja-Isavadharm, P | 1 |
Walker, L | 1 |
Redig, AJ | 1 |
Vaidya, A | 1 |
Price, C | 1 |
Katz, JT | 1 |
Maguire, JH | 1 |
Ingram, RJ | 1 |
Crenna-Darusallam, C | 1 |
Soebianto, S | 1 |
Noviyanti, R | 3 |
Satyagraha, AW | 1 |
Sadhewa, A | 1 |
Baramuli, V | 1 |
Elvira, R | 1 |
Ridenour, C | 1 |
Elyazar, I | 2 |
Coutrier, FN | 1 |
Harahap, AR | 1 |
Fernando, SD | 1 |
Baird, K | 1 |
Cheoymang, A | 1 |
Ruenweerayut, R | 1 |
Muhamad, P | 1 |
Rungsihirunrat, K | 1 |
Na-Bangchang, K | 1 |
Erhardt, J | 1 |
Frank, M | 1 |
Rodriguez, MH | 2 |
Sandoval, MA | 1 |
Santillan, F | 1 |
Galindo-Virgen, S | 1 |
Betanzos, AF | 1 |
Rosales, AF | 1 |
Palomeque, OL | 1 |
McFarland, AP | 1 |
Sanchez, JF | 1 |
Mercado, A | 1 |
Ventocilla, JA | 1 |
Cavalcanti, S | 1 |
Gonzalez, S | 1 |
Siala, E | 1 |
Gastli, M | 1 |
Essid, R | 1 |
Jemal, S | 1 |
Ben Abdallah, R | 1 |
Ben Abda, I | 1 |
Aoun, K | 1 |
Bouratbine, A | 1 |
Nelwan, EJ | 1 |
Tjahjono, B | 1 |
Setiabudy, R | 1 |
Ekasari, T | 1 |
Djoko, D | 1 |
Basri, H | 3 |
Taylor, WR | 2 |
Subekti, D | 1 |
Savargaonkar, D | 1 |
Nagpal, BN | 1 |
Srivastava, B | 1 |
Anvikar, AR | 1 |
Tamayo Perez, ME | 1 |
Aguirre-Acevedo, DC | 1 |
Rishikesh, K | 1 |
Richter, J | 1 |
Franken, G | 1 |
Holtfreter, MC | 1 |
Walter, S | 1 |
Labisch, A | 1 |
Mehlhorn, H | 1 |
Silvino, AC | 1 |
Costa, GL | 1 |
Araújo, FC | 1 |
Ascher, DB | 1 |
Pires, DE | 1 |
Brito, CF | 1 |
Negreiros, S | 1 |
Viana, GM | 1 |
Okoth, SA | 1 |
de Souza, TM | 1 |
Udhayakumar, V | 1 |
Povoa, MM | 1 |
Santelli, AC | 1 |
de Oliveira, AM | 1 |
Menard, D | 1 |
Kheng, S | 1 |
Mayan, I | 1 |
Mohammed, N | 1 |
Erasmus, P | 1 |
Kolaczinski, J | 1 |
Whitty, CJ | 1 |
Hanf, M | 1 |
Stéphani, A | 1 |
Orjuela-Sánchez, P | 1 |
da Silva, NS | 1 |
da Silva-Nunes, M | 1 |
Redmond, P | 1 |
O'Shea, B | 1 |
Crowe, M | 1 |
Chiang, TY | 1 |
Lin, WC | 1 |
Kuo, MC | 1 |
Ji, DD | 1 |
Fang, CT | 1 |
Kim, JR | 2 |
Nandy, A | 2 |
Maji, AK | 1 |
Addy, M | 1 |
Pedro, RS | 1 |
Guaraldo, L | 1 |
Campos, DP | 1 |
Costa, AP | 1 |
Daniel-Ribeiro, CT | 1 |
Brasil, P | 1 |
Kiniboro, B | 1 |
Stanisic, DI | 1 |
Samol, L | 1 |
de Lazzari, E | 1 |
Del Portillo, HA | 2 |
Siba, P | 1 |
Alonso, PL | 1 |
Bassat, Q | 1 |
Wiady, I | 2 |
Sutanihardja, A | 1 |
Ayomi, E | 1 |
Fryauff, DJ | 2 |
Hoffman, SL | 2 |
Durante Mangoni, E | 1 |
Severini, C | 1 |
Menegon, M | 1 |
Romi, R | 1 |
Ruggiero, G | 1 |
Majori, G | 1 |
Mehrunnisa, A | 1 |
Saifi, MA | 1 |
Khan, HM | 1 |
HANSEN, JE | 1 |
CLEVE, EA | 1 |
PRUITT, FW | 1 |
ARNOLD, J | 1 |
ALVING, AS | 1 |
HOCKWALD, RS | 1 |
CLAYMAN, CB | 1 |
DERN, RJ | 1 |
BEUTLER, E | 1 |
JEFFERY, GM | 2 |
Bottieau, E | 2 |
Van Gompel, A | 2 |
Peetermans, WE | 1 |
Clerinx, J | 1 |
Van Den Enden, E | 2 |
Van Esbroeck, M | 1 |
Colebunders, R | 1 |
Van Den Ende, J | 2 |
Hill, DR | 1 |
Parise, ME | 1 |
Lewis, LS | 1 |
Ryan, ET | 1 |
Magill, AJ | 2 |
Reddy, P | 1 |
Flaherty, JP | 1 |
Tanomsing, N | 1 |
Guthmann, JP | 1 |
Carlton, J | 1 |
Looareesuwan, S | 4 |
Nair, S | 1 |
Sudimack, D | 1 |
Anderson, TJ | 1 |
Coldren, RL | 1 |
Vayakornvichit, S | 1 |
Noedl, H | 1 |
Fukudas, MM | 1 |
Tangpukdee, N | 1 |
Wilairatana, P | 3 |
Phophak, N | 1 |
Brittenham, GM | 1 |
Wang, K | 1 |
Liu, YL | 1 |
Zhang, PN | 1 |
Liu, JX | 1 |
Appavoo, NC | 1 |
Roy, RG | 2 |
Kapali, V | 1 |
Vittal, M | 1 |
Bhate, MR | 1 |
Shinde, PH | 1 |
Deshpande, SV | 1 |
Krotoski, WA | 2 |
Horstmann, P | 1 |
Jelinek, T | 1 |
Nothdurft, HD | 2 |
Von Sonnenburg, F | 1 |
Loscher, T | 2 |
Van den Abbeele, K | 1 |
Lazar, AI | 1 |
Cranfield, MR | 1 |
Graczyk, TK | 1 |
Beall, FB | 1 |
Ialeggio, DM | 1 |
Shaw, ML | 1 |
Skjoldager, ML | 1 |
Vanijanonta, S | 1 |
Chantra, A | 1 |
Clemens, R | 2 |
Rønn, AM | 1 |
Bygbjerg, IC | 1 |
Obana, M | 1 |
Ohta, S | 1 |
Matsuoka, Y | 1 |
Irimajiri, S | 1 |
Kano, S | 1 |
Suzuki, M | 1 |
Toma, E | 2 |
Fournier, S | 2 |
Dumont, M | 1 |
Bolduc, P | 1 |
Deschamps, H | 1 |
Weinke, T | 1 |
Kretschmer, H | 1 |
Fleischer, K | 1 |
Braendli, B | 1 |
Markwalder, K | 1 |
Schlunk, T | 1 |
Bock, HL | 1 |
Signorini, L | 1 |
Matteelli, A | 1 |
Castelnuovo, F | 1 |
Castelli, F | 1 |
Oladeji, O | 1 |
Carosi, G | 1 |
Kimura, M | 1 |
Tomizawa, I | 1 |
Takizawa, Y | 1 |
Ohtomo, H | 2 |
Smoak, BL | 1 |
DeFraites, RF | 1 |
Kain, KC | 2 |
Wellde, BT | 1 |
Bangs, MJ | 1 |
Subianto, B | 1 |
Harjosuwarno, S | 1 |
Tjitra, E | 1 |
Richie, TL | 1 |
Srivastava, HC | 1 |
Sharma, SK | 1 |
Bhatt, RM | 1 |
Sharma, VP | 4 |
Nayar, JK | 1 |
Baker, RH | 1 |
Knight, JW | 1 |
Sullivan, JS | 2 |
Morris, CL | 2 |
Richardson, BB | 2 |
Galland, GG | 2 |
Collins, WE | 4 |
Telgt, DS | 1 |
Mulder, L | 1 |
Dolmans, WM | 1 |
Buchachart, K | 1 |
Chalermrut, K | 2 |
Rattanapong, Y | 1 |
Amradee, S | 1 |
Siripiphat, S | 1 |
Chullawichit, S | 1 |
Thimasan, K | 1 |
Ittiverakul, M | 1 |
Triampon, A | 1 |
Walsh, DS | 1 |
Yi, KJ | 1 |
Chung, MH | 1 |
Kim, HS | 1 |
Kim, CS | 1 |
Pai, SH | 1 |
Nguyen-Dinh, P | 1 |
Nesby, S | 1 |
Na, DJ | 1 |
Han, JD | 1 |
Cha, DY | 1 |
Song, IK | 1 |
Choi, HW | 1 |
Chung, EA | 1 |
Park, CW | 1 |
Choi, JS | 1 |
da Cunha, MG | 1 |
Silva, MN | 1 |
Souza, JM | 1 |
Rodrigues, MM | 1 |
Treeprasertsuk, S | 1 |
Singhasivanon, P | 1 |
Bussaratid, V | 1 |
Chokjindachai, W | 1 |
Viriyavejakul, P | 1 |
Walsh D, S | 1 |
White, J | 1 |
Hernandez, JE | 1 |
Nettel, JA | 1 |
Villarreal, C | 1 |
Wirtz, RA | 1 |
Kroeger, A | 1 |
Nicolas, X | 1 |
Granier, H | 1 |
Martin, J | 1 |
Klotz, F | 1 |
Duarte, EC | 1 |
Pang, LW | 1 |
Ribeiro, LC | 1 |
Dua, VK | 2 |
Khatri, TD | 1 |
Owusu-Agyei, S | 1 |
Binka, F | 1 |
Koram, K | 1 |
Anto, F | 1 |
Adjuik, M | 1 |
Nkrumah, F | 1 |
Smith, T | 1 |
Clyde, DF | 1 |
McCarthy, VC | 1 |
Chakrapani, KP | 1 |
Dhinagaran, D | 1 |
Sitaraman, NL | 1 |
Ghosh, RB | 1 |
Saint-Yves, IF | 1 |
Rossan, RN | 1 |
Young, MD | 1 |
Baerg, DC | 1 |
Noskin, GA | 1 |
Murphy, RL | 1 |
Black, JR | 1 |
Phair, JP | 1 |
Nathwani, D | 1 |
Currie, PF | 1 |
Smith, CC | 1 |
Khaund, R | 1 |
Stewart, NP | 1 |
de Vos, AJ | 1 |
Shiels, I | 1 |
Tanabe, K | 2 |
Shimada, K | 1 |
Sharma, RC | 1 |
Gautam, AS | 1 |
Orlov, V | 1 |
Kay, R | 1 |
DuBois, RE | 1 |
Poisson, M | 1 |
Morisset, R | 1 |
Phaneuf, D | 1 |
Vega, C | 1 |
Sinha, S | 1 |
McGlone, R | 1 |
Mulik, R | 1 |
Rombo, L | 1 |
Edwards, G | 1 |
Ward, SA | 1 |
Eriksson, G | 1 |
Lindquist, L | 1 |
Lindberg, A | 1 |
Runehagen, A | 1 |
Hylander, NO | 1 |
Hioki, A | 1 |
Nakabayashi, T | 1 |
Ishizaki, T | 1 |
Yang, BL | 1 |
Wan, WJ | 1 |
Wang, WR | 1 |
Hu, HX | 1 |
Li, HX | 1 |
Li, XL | 1 |
Li, CZ | 1 |
Huang, GZ | 1 |
Kumar, A | 1 |
Dutta, GP | 1 |
Charoenlarp, P | 1 |
Harinasuta, T | 1 |
Contacos, PG | 2 |
Chin, W | 1 |
Jeter, MH | 1 |
Briesch, PE | 1 |
Barrett-Connor, E | 1 |
Howard, WA | 1 |
Knüttgen, H | 1 |
Bruce-Chwatt, LJ | 1 |
Clinical Trials (22)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil[NCT03610399] | 257 participants (Actual) | Interventional | 2018-04-09 | Completed | |||
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos[NCT02802813] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2016-06-14 | Completed | ||
"Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"[NCT03241901] | Phase 4 | 280 participants (Actual) | Interventional | 2017-07-27 | Completed | ||
Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934] | Phase 4 | 524 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru[NCT05361486] | 40 participants (Anticipated) | Observational | 2023-08-28 | Recruiting | |||
Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand[NCT05052502] | 49,118 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic[NCT04416945] | 31,443 participants (Anticipated) | Interventional | 2020-09-20 | Recruiting | |||
A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408] | Phase 4 | 320 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905] | Phase 3 | 655 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax[NCT01640574] | Phase 3 | 680 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens[NCT01814683] | 2,388 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults[NCT05071079] | 16 participants (Anticipated) | Interventional | 2022-05-23 | Recruiting | |||
Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naï[NCT01157897] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico[NCT02394197] | Phase 4 | 153 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia[NCT05829187] | Phase 2 | 36 participants (Actual) | Interventional | 2022-11-01 | Completed | ||
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua[NCT06036030] | Phase 2 | 50 participants (Actual) | Interventional | 2019-01-11 | Completed | ||
A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.[NCT00158587] | Phase 3 | 150 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095] | Early Phase 1 | 18 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 168 days
Intervention | participants (Number) |
---|---|
Primaquine Regular Dose Unsupervised | 29 |
Primaquine Regular Dose Supervised | 44 |
Primaquine Double Dose Unsupervised | 67 |
Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 28 days
Intervention | participants (Number) |
---|---|
Primaquine Regular Dose Unsupervised | 61 |
Primaquine Regular Dose Supervised | 88 |
Primaquine Double Dose Unsupervised | 90 |
Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168
Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites. (NCT03610399)
Timeframe: 168 days
Intervention | Participants (Number) |
---|---|
Primaquine Regular Dose Unsupervised | 29 |
Primaquine Regular Dose Supervised | 44 |
Primaquine Double Dose Unsupervised | 67 |
Time to Parasitemia for Immunogenicity Population
"Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.~Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy." (NCT01157897)
Timeframe: 280 day (during the study through 6 months aftr challenge)
Intervention | days (Mean) |
---|---|
Cohort 1: 15 μg VMP001 | 0.137 |
Cohort 2: 30 μg VMP001 | 0.073 |
Cohort 3: 60 μg VMP001 | 0.042 |
Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration
Intervention | Geometric Mean Titier of European Units (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Pre-vaccination | 2wks post first vaccination | Day of second vaccination | 2wks post second vaccination | Day of third vaccination | 2wks post third vaccination | 4wks post challenge | 6mths post challenge | |
Cohort 1: 15 μg VMP001 | 1 | 133.72 | 244.35 | 20161.18 | 9053.32 | 61203.48 | 54843.38 | 10860.7 |
Cohort 2: 30 μg VMP001 | 1 | 750.38 | 1450.22 | 81143.72 | 31071.01 | 68730.4 | 56472.17 | 12519.16 |
Cohort 3: 60 μg VMP001 | 3.09 | 836.68 | 1711.63 | 61711.8 | 36405.66 | 41879.99 | 32178.39 | 5500.73 |
Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration
Intervention | Geometric Mean Titer of European Units (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Pre-vaccination | 2wks post first vaccination | Day of second vaccination | 2wks post second vaccination | Day of third vaccination | 2wks post third vaccination | 4wks post challenge | 6months post challenge | |
Cohort 1: 15 μg VMP001 | 1 | 151.39 | 281.79 | 21862.22 | 9921.61 | 59883.77 | 54843.38 | 10860.7 |
Cohort 2: 30 μg VMP001 | 1.5 | 526.18 | 1175.41 | 74608.62 | 28498.43 | 68730.4 | 56472.17 | 12519.16 |
Cohort 3: 60 μg VMP001 | 3.09 | 836.68 | 1711.63 | 61711.8 | 36405.66 | 41879.99 | 32178.39 | 5500.73 |
Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase
Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. (NCT01157897)
Timeframe: 7 days after immunization
Intervention | participants with AEs (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Solicited Local: Injection site erythema | Solicited Local: Injection site induration | Solicited Local: Injection site pain | Solicited Systemic: Diarrhea | Solicited Systemic: Nausea | Solicited Systemic: Vomiting | Solicited Systemic: Fatigue | Solicited Systemic: Pyrexia | Solicited Systemic: Arthralgia | Solicited Systemic: Myalgia | Solicited Systemic: Headache | |
Cohort 1: 15 μg VMP001 | 2 | 0 | 10 | 0 | 5 | 2 | 8 | 4 | 4 | 4 | 8 |
Cohort 2: 30 μg VMP001 | 3 | 1 | 10 | 0 | 3 | 0 | 4 | 2 | 2 | 4 | 6 |
Cohort 3: 60 μg VMP001 | 6 | 2 | 10 | 1 | 4 | 2 | 7 | 1 | 3 | 7 | 5 |
Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase
Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase (NCT01157897)
Timeframe: 28 days following immunization
Intervention | participants with AEs (Number) | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ear discomfort | Abdominal discomfort | Abdominal pain | Feces discolored | Food poisoning | Nausea | Toothache | Axillary pain | Chills | Feeling hot | Injection site erythema | Injection site pruritus | Injection site swelling | Injection site warmth | Malaise | Hypertransaminasaemia | Seasonal allergy | Nasopharyngitis | Upper respiratory tract infection | Contusion | Excoriation | Postprocedural discomfort | Posttraumatic pain | Scratch | Skin laceration | Haemoglobin decreased | Platelet count decreased | Gout | Back pain | Muscle spasms | Musculoskeletal discomfort | Myalgia | Pain in extremity | Dizziness | Headache | Sinus headache | Nasal Congestion | Cold sweat | Dermatitis contact | Erythema | Hypertension | |
Cohort 1: 15 μg VMP001 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 |
Cohort 2: 30 μg VMP001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 6 | 0 | 0 | 2 | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 0 |
Cohort 3: 60 μg VMP001 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 7 | 7 | 1 | 1 | 3 | 2 | 7 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
Infection for P. Vivax
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
Intervention | days (Mean) |
---|---|
Group 1 | 11 |
Group 2 | 11 |
Group 3 | 9 |
Reviews
16 reviews available for primaquine and Recrudescence
Article | Year |
---|---|
Tafenoquine for the treatment of
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Tafenoquine for
Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu | 2021 |
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Topics: Antimalarials; Folic Acid Antagonists; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurre | 2023 |
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Vivax; Plas | 2019 |
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Topics: Adult; Antimalarials; Child; Drug Administration Schedule; Glucosephosphate Dehydrogenase; Humans; M | 2020 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D | 2020 |
Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.
Topics: Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Ma | 2018 |
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 2018 |
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine; Primary Prevention; | 2019 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V | 2015 |
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.
Topics: Anemia; Antimalarials; Chemical and Drug Induced Liver Injury; Glucosephosphate Dehydrogenase Defici | 2015 |
Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Administration Schedule; Humans; Malaria, | 2015 |
Primaquine treatment and relapse in Plasmodium vivax malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax; Primaquine; Recurrence; Treatm | 2016 |
Clinical implications of a gradual dormancy concept in malaria.
Topics: Aminoquinolines; Antimalarials; Humans; Liver; Malaria; Parasitemia; Plasmodium; Plasmodium falcipar | 2016 |
Management of relapsing Plasmodium vivax malaria.
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Humans; Liver; | 2016 |
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans; | 2000 |
Trials
33 trials available for primaquine and Recrudescence
Article | Year |
---|---|
Higher-Dose Primaquine to Prevent Relapse of
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Directly Obser | 2022 |
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Female; Humans; Infant; Malaria, Vivax; M | 2019 |
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Asymptomatic Infections; Female; Humans; Laos; Malar | 2020 |
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum | 2020 |
Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool | 2020 |
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho | 2017 |
The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.
Topics: Biomedical Research; Double-Blind Method; Ethics, Research; Humans; Malaria, Vivax; Patient Selectio | 2018 |
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
Topics: Adult; Aged; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; India; Malaria, Vivax; | 2018 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Administration | 2019 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc | 2014 |
Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dia | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Drug Adm | 2008 |
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Female; Genotype; Genotyping Techniq | 2012 |
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Female; Humans | 2012 |
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Topics: Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Incidence; Indonesia; Malaria, Falcip | 2002 |
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; Humans; India; Malaria, | 2007 |
High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 2008 |
Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
Topics: Adolescent; Adult; Aged; Child; Chloroquine; Drug Therapy, Combination; Female; Germany; Humans; Mal | 1995 |
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Follow-Up Studi | 1994 |
Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Clindamycin; Double-Blind Method; Drug Therapy, Combin | 1993 |
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Drug Therapy, Combination; Drug Tolerance; Female; | 1993 |
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia; | 1997 |
Chloroquine sensitivity of Plasmodium vivax in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Mala | 1999 |
Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
Topics: Antimalarials; Drug Administration Schedule; Follow-Up Studies; Humans; India; Malaria, Vivax; Prima | 2001 |
Does radical cure of asymptomatic Plasmodium falciparum place adults in endemic areas at increased risk of recurrent symptomatic malaria?
Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Doxycycline; Drug Administration Schedule; Drug Th | 2002 |
Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine.
Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Follow-Up Studies; Humans; Malaria; Male; Plasmodi | 1977 |
Clindamycin with primaquine for Pneumocystis carinii pneumonia.
Topics: Administration, Oral; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up St | 1989 |
Combined chloroquine-primaquine therapy against vivax malaria.
Topics: Chloroquine; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Malaria; Plasmodium vivax | 1974 |
Other Studies
123 other studies available for primaquine and Recrudescence
Article | Year |
---|---|
Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives.
Topics: Animals; Antimalarials; Crystallography, X-Ray; Guanidines; Humans; Imidazoles; Imidazolines; In Vit | 2011 |
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Cross-Sectional Studies; Disease Eradicat | 2021 |
Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria, Vivax; Plasmodiu | 2022 |
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study.
Topics: Antimalarials; Cohort Studies; Humans; Malaria, Vivax; Primaquine; Recurrence | 2022 |
Tafenoquine for the prevention of Plasmodium vivax malaria relapse.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2021 |
Cost-Benefit Analysis of Tafenoquine for Radical Cure of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrenc | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
How does primaquine prevent Plasmodium vivax malarial recurrences?
Topics: Animals; Antimalarials; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Cytochrome P450 Family 2; Humans; Malaria, Vivax; Phenotype; | 2022 |
Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Medication Adherence; Myanmar; Plasmodium vivax; Pri | 2023 |
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Cytochrome P-450 CYP2D6; Ghana; Humans; Inacti | 2019 |
Killing of Plasmodium vivax by Primaquine and Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaqu | 2019 |
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte | 2020 |
Malaria resurgence after significant reduction by mass drug administration on Ngodhe Island, Kenya.
Topics: Anemia; Animals; Antimalarials; Geography; Hemoglobins; Humans; Islands; Kenya; Malaria; Mass Drug A | 2019 |
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Brazil; Child; Cytochrome P-450 CYP2D6; Fem | 2020 |
Cost-Effectiveness Analysis of Sex-Stratified
Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Ana | 2020 |
Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
Topics: Antimalarials; Artemisinins; Asian People; Cambodia; Cytochrome P-450 CYP2D6; Drug Therapy, Combinat | 2020 |
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Cytochrome P-450 CYP2D6 | 2020 |
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Phenotype; Plasmodium vivax; | 2020 |
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans; | 2020 |
Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Vivax; Male; Middle A | 2021 |
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Plasmodium ovale; Plasmodium vivax; | 2022 |
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Dr | 2017 |
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Drug Resistance; Follow-Up Studies; Genotype; Huma | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
A clinical tool to predict Plasmodium vivax recurrence in Malaysia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Area Under Curve; Child; Chi | 2017 |
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Topics: Antimalarials; Asia, Southeastern; Cytochrome P-450 CYP2D6; Glucosephosphate Dehydrogenase Deficienc | 2018 |
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cytochrome P-450 CYP | 2018 |
Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection.
Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Austria; Communicable Diseases | 2018 |
A Malaria Case Followed By Relapse.
Topics: Animals; Anopheles; Antimalarials; Chronic Disease; Diagnosis, Differential; Humans; Malaria, Vivax; | 2018 |
A 38-year-old man with fever and a history of malaria.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Malaria, Vivax; Male; Pri | 2018 |
Tafenoquine - A Radical Improvement?
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2019 |
Evaluation of Plasmodium vivax malaria recurrence in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Brazil; Child; Child, Presc | 2019 |
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Drug Therapy, Combination; Female; F | 2019 |
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Topics: Alleles; Antimalarials; Australia; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Military Personn | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule | 2019 |
A shorter course for anti-relapse therapy against vivax malaria.
Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Primaquine; Recurrence | 2019 |
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Drug Tolerance; Genome, Protozoan; High-Throug | 2013 |
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaqu | 2014 |
The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.
Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Prescriptions; Female; Follow-Up Studie | 2013 |
Realistically, how far are we from a universal malaria drug?
Topics: Antimalarials; Artemisinins; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Malaria; P | 2014 |
A retrospective study on imported malaria in Jordan. 1. Malaria among Jordanian UN peacekeeping forces.
Topics: Adult; Antimalarials; Cote d'Ivoire; Doxycycline; Drug Therapy, Combination; Endemic Diseases; Eritr | 2014 |
Imported malaria is stable from Africa but declining from Asia.
Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre | 2014 |
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini | 2014 |
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther | 2014 |
Interactive medical case. A chilly fever.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Life Cycle Stages; Malari | 2014 |
The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
Topics: Antimalarials; Doxycycline; Female; Humans; Malaria, Vivax; Middle Aged; New Zealand; Papua New Guin | 2014 |
G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Female; | 2015 |
Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Male; | 2015 |
[13-year old girl with fever 6 months after returning from sub-Saharan Africa].
Topics: Adolescent; Africa; Chloroquine; Developing Countries; Female; Fever of Unknown Origin; Germany; Hum | 2015 |
Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
Topics: Adult; Antimalarials; Body Weight; Genotype; Genotyping Techniques; Humans; Malaria, Vivax; Male; Mi | 2015 |
Late relapse of imported Plasmodium ovale malaria: a case report.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Cote d'Ivoire; Drug C | 2015 |
The footprints of relapsing malaria in southwest Delhi, India.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Female; Humans; India; Infant; Malaria; Male; Pr | 2015 |
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
Topics: Adolescent; Adult; Antimalarials; Child; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Female; G | 2016 |
Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy, | 2016 |
Modelling primaquine-induced haemolysis in G6PD deficiency.
Topics: Anemia, Hemolytic; Antimalarials; Bayes Theorem; Cell Death; Erythrocytes; Female; Glucosephosphate | 2017 |
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
Topics: Animals; Antimalarials; Chloroquine; Cohort Studies; Female; Follow-Up Studies; French Guiana; Human | 2009 |
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi | 2009 |
'Not another UTI ... '.
Topics: Aged, 80 and over; Antimalarials; Fever; Humans; Malaria; Male; Plasmodium ovale; Primaquine; Recurr | 2012 |
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
Topics: Adult; Antimalarials; DNA, Protozoan; Genotype; Humans; Malaria, Vivax; Male; Middle Aged; Oceania; | 2012 |
Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
Topics: Adolescent; Adult; Animals; Antimalarials; Brazil; Female; Humans; Malaria, Vivax; Male; Middle Aged | 2012 |
Reinventing primaquine for endemic malaria.
Topics: Antimalarials; Dose-Response Relationship, Drug; Endemic Diseases; Glucosephosphate Dehydrogenase De | 2012 |
Case report: An unusual late relapse of Plasmodium vivax malaria.
Topics: Animals; Antimalarials; Chloroquine; Diagnosis, Differential; DNA, Protozoan; Drug Administration Sc | 2003 |
Prevalence of malaria in Aligarh.
Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India; | 2002 |
Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine.
Topics: Antimalarials; Chronic Disease; Cyanosis; Humans; Malaria; Malaria, Vivax; Methemoglobinemia; Primaq | 1954 |
The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria.
Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Recurrence | 1954 |
Failure of primaquine therapy for the treatment of Plasmodium ovale malaria.
Topics: Adolescent; Adult; Antimalarials; Humans; Malaria; Male; Plasmodium ovale; Primaquine; Recurrence; T | 2005 |
Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Europe; Female; Geography; Humans; Malaria; | 2006 |
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
Topics: Adult; Antimalarials; Centers for Disease Control and Prevention, U.S.; Child; Clinical Trials as To | 2006 |
Plasmodium vivax malaria relapses after primaquine prophylaxis.
Topics: Aged; Antimalarials; Humans; Malaria, Vivax; Male; Primaquine; Recurrence | 2006 |
Apparent relapse of imported Plasmodium ovale malaria in a pregnant woman.
Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria; Plasmodium ovale; Pregnancy; Pr | 2007 |
[Relapses and indirect fluorescent antibody level in vivax malaria patients after chloroquine and chloroquine-primaquine treatment].
Topics: Antibodies; Chloroquine; Fluorescent Antibody Technique; Humans; Malaria; Plasmodium vivax; Primaqui | 1984 |
Results of 3-day radical treatment of Plasmodium vivax in North Arcot and South Arcot Districts of Tamil Nadu.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; Humans; | 1984 |
A note on an interesting case of treatment of Plasmodium vivax curative therapy relapses in a four year old child from Aurangabad, Maharashtra State, India.
Topics: Child, Preschool; Female; Humans; India; Malaria; Plasmodium vivax; Primaquine; Recurrence | 1982 |
Frequency of relapse and primaquine resistance in Southeast Asian vivax malaria.
Topics: Asia, Southeastern; Drug Resistance, Microbial; Humans; Malaria; Plasmodium vivax; Primaquine; Recur | 1980 |
[Prevention of recurrence of malaria with primaquine].
Topics: Adult; Child; Child, Preschool; Chloroquine; Follow-Up Studies; Humans; Malaria; Male; Middle Aged; | 1982 |
Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India.
Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Prim | 1995 |
Halofantrine in acute malaria.
Topics: Acute Disease; Antimalarials; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax | 1994 |
Subclinical avian malaria infections in African black-footed penguins (Spheniscus demersus) and induction of parasite recrudescence.
Topics: Animals; Animals, Zoo; Baltimore; Birds; Chloroquine; Dexamethasone; Ducks; Immunosuppression Therap | 1994 |
[Recurrence problems with preventive primaquine treatment in patients with malaria].
Topics: Adult; Drug Resistance, Microbial; Gastrointestinal Diseases; Humans; Malaria, Falciparum; Malaria, | 1993 |
[A case of vivax malaria in which remission was achieved by primaquine at 1.5 times the standard dose after two earlier relapses].
Topics: Adult; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Primaquine; Recurrence; Remission | 1993 |
Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1996 |
[A study of relapsed cases of vivax malaria after the standard primaquine therapy].
Topics: Adult; Antimalarials; Asia, Southeastern; Drug Administration Schedule; Humans; Japan; Malaria, Viva | 1996 |
Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
Topics: Adolescent; Adult; Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Mefloquine | 1997 |
Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; F | 1996 |
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist | 1997 |
[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
Topics: Adult; Antimalarials; Drug Tolerance; Female; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; | 1997 |
Primaquine-tolerant vivax malaria in Thailand.
Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu | 1997 |
A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy.
Topics: Adult; Animals; Antimalarials; Humans; Hydroxychloroquine; Malaria, Vivax; Male; Primaquine; Recurre | 1998 |
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models, | 1998 |
Imported tertian malaria resistant to primaquine.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Pla | 1999 |
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1.
Topics: Adult; Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Enzyme-Linked Immunosorbe | 1999 |
Different prevalences of Plasmodium vivax phenotypes VK210 and VK247 associated with the distribution of Anopheles albimanus and Anopheles pseudopunctipennis in Mexico.
Topics: Altitude; Animals; Anopheles; Antibodies, Monoclonal; Antibodies, Protozoan; Antimalarials; Chloroqu | 2000 |
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria, | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
Topics: Animals; Antimalarials; Humans; India; Malaria, Vivax; Plasmodium vivax; Polymerase Chain Reaction; | 2002 |
Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu.
Topics: Adult; Child; Chloroquine; Follow-Up Studies; Humans; India; Malaria; Plasmodium vivax; Primaquine; | 1977 |
Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands.
Topics: Adolescent; Adult; Child; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria; Male; | 1977 |
Chemotherapy of Plasmodium vivax in Saimiri and Aotus models.
Topics: Administration, Oral; Animals; Chloroquine; Disease Models, Animal; Drug Combinations; Drug Evaluati | 1975 |
Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clindamycin; Drug Therapy, Combination; Female; Human | 1992 |
Recurrent plasmodium ovale infection from Papua New Guinea--chloroquine resistance or inadequate primaquine therapy?
Topics: Adult; Humans; Malaria; Male; New Guinea; Primaquine; Recurrence | 1991 |
Elimination of Theileria buffeli infections from cattle by concurrent treatment with primaquine phosphate and halofuginone lactate.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Apicomplexa; Cattle; Drug Therapy, Combination | 1990 |
[Clinical evaluation of antimalarial drugs].
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Evaluation; Female; Humans; Malaria; Male; Plasmodi | 1990 |
Relapse pattern of Plasmodium vivax in Kheda district, Gujarat.
Topics: Animals; Chloroquine; Drug Therapy, Combination; Humans; India; Malaria; Plasmodium vivax; Primaquin | 1990 |
Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Clindamycin; Drug Administration Sc | 1990 |
Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.).
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria; M | 1989 |
Hypnozoites in Bradford.
Topics: Animals; Child, Preschool; Chloroquine; England; Fever; Humans; Infant, Newborn; Malaria; Male; Plas | 1988 |
Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment.
Topics: Adult; Female; Humans; Infant; Malaria; Male; Patient Compliance; Plasmodium; Plasmodium vivax; Prim | 1987 |
Clinical evaluation of antimalarial regimens in Japan.
Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Japan; Malaria; Plasmodium f | 1987 |
[Experimental studies on the biological characteristics of Plasmodium vivax in south Yunnan].
Topics: Animals; Anopheles; China; Chloroquine; Humans; Malaria; Plasmodium vivax; Primaquine; Recurrence | 1986 |
Tissue schizontocidal activity of minocycline against a relapsing malaria parasite Plasmodium cynomolgi B.
Topics: Animals; Female; Macaca mulatta; Malaria; Male; Minocycline; Plasmodium; Primaquine; Recurrence; Tet | 1987 |
Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase; | 1973 |
Chemoprophylaxis of malaria for travelers.
Topics: Africa; Antimalarials; Asia; Central America; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug | 1974 |
Studies on the characterization of plasmodium vivax strains from Central America.
Topics: Animals; Central America; Chloroquine; Haplorhini; Humans; Lincomycin; Malaria; Plasmodium vivax; Pr | 1972 |
[Letter: Primary long latency in malaria].
Topics: Chloroquine; Malaria; Primaquine; Recurrence; Time Factors | 1973 |
The role of drugs in a malaria program.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui | 1972 |